Literature DB >> 17922043

The impact of histologic grade on the outcome of high-dose therapy and autologous stem cell transplantation for follicular lymphoma.

R N Pham1, T A Gooley, G E Keeney, O W Press, J M Pagel, H A Greisman, W I Bensinger, L A Holmberg, S H Petersdorf, D G Maloney, A K Gopal.   

Abstract

The impact of the follicular lymphoma (FL) histologic grade on outcomes after high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) is unknown. We evaluated 219 consecutive patients with grades 1-3 FL who underwent HDT and ASCT at our center. Overall survival (OS), progression-free survival (PFS), relapse and non-relapse mortality (NRM) was estimated for each grade after controlling for other predictive factors. The number of patients with grades 1, 2 and 3 FL was 106 (48%), 75 (34%) and 38 (17%), respectively. Five-year outcome estimates for the entire cohort included 60% OS, 39% PFS and 46% relapse (median follow-up=7.8 years). PFS and relapse were nearly identical among patients with grade 3 FL versus grades 1-2 FL after adjusting for other contributing factors (hazard ratio (HR)=0.90, P=0.68; HR=1.07, P=0.80, respectively). The hazard for mortality (HR=0.70, P=0.23) and NRM (HR=0.33, P=0.07) was non-significantly lower among patients with grade 3 FL compared to patients with grades 1-2 disease. Factors associated with inferior PFS included elevated lactate dehydrogenase (HR=1.52, P=0.03), chemoresistance (HR=1.82, P=0.02), > or =2 prior therapies (HR=1.8, P=0.03) and prior radiation (HR=1.99, P=0.003). These data suggest that the histologic grade of FL does not impact PFS or relapse following HDT and ASCT.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17922043     DOI: 10.1038/sj.bmt.1705864

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  1 in total

1.  Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma.

Authors:  E Klyuchnikov; U Bacher; K Woo Ahn; J Carreras; N M Kröger; P N Hari; G H Ku; E Ayala; A I Chen; Y-B Chen; J B Cohen; C O Freytes; R P Gale; R T Kamble; M A Kharfan-Dabaja; H M Lazarus; R Martino; A Mussetti; B N Savani; H C Schouten; S Z Usmani; P H Wiernik; B Wirk; S M Smith; A Sureda; M Hamadani
Journal:  Bone Marrow Transplant       Date:  2015-10-05       Impact factor: 5.483

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.